Chelsi Flippo1,2, Vipula Kolli3, Melissa Andrew2, Seth Berger4, Tricia Bhatti5, Alison M Boyce6, Daniel Casella7, Michael T Collins8, Emmanuèle Délot9, Joseph Devaney10, Stephen M Hewitt11, Thomas Kolon12, Ashwini Mallappa3, Perrin C White13, Deborah P Merke1,3, Andrew Dauber2,14. 1. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, Maryland 20892, USA. 2. Division of Endocrinology, Children's National Hospital, Washington, DC 20010, USA. 3. National Institutes of Health Clinical Center, Bethesda, Maryland 20892, USA. 4. Center for Genetic Medicine Research & Rare Disease Institute, Children's National Hospital, Washington, DC 20012, USA. 5. Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia and The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. 6. Metabolic Bone Disorders Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland 20892, USA. 7. Division of Pediatric Urology, Children's National Hospital, Washington, DC 20010, USA. 8. Skeletal Disorders and Mineral Homeostasis Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland 20892, USA. 9. Center for Genetic Medicine Research, Children's National Research Institute and Department of Genomics and Precision Medicine, George Washington University, Washington, DC 20012, USA. 10. GeneDx, Gaithersburg, Maryland 20877, USA. 11. Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20814, USA. 12. Children's Hospital of Philadelphia, Perelman School of Medicine at University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. 13. Division of Pediatric Endocrinology, UT Southwestern Medical Center, Dallas, Texas 75230, USA. 14. Department of Pediatrics, The George Washington University School of Medicine and Health Sciences, Washington, DC 20052, USA.
Abstract
Context: Autosomal dominant and rarely de novo gain-of-function variants in the LHCGR gene are associated with precocious male puberty, while somatic LHCGR variants have been found in isolated Leydig cell adenomas and Leydig cell hyperplasia. Bilateral diffuse Leydig cell tumor formation in peripheral precocious male puberty has not been reported. Case Description: We present a boy with gonadotropin-independent precocious puberty and rapid virilization beginning in infancy resistant to standard therapy. Treatment with abiraterone in addition to letrozole and bicalutamide proved effective. Bilateral diffuse Leydig cell tumors were identified at age 5 years. Results: Whole-genome sequencing of tumor and blood samples was performed. The patient was confirmed to have bilateral, diffuse Leydig cell tumors harboring the somatic, gain-of-function p.Asp578His variant in the LHCGR gene. Digital droplet polymerase chain reaction of the LHCGR variant performed in tumor and blood samples detected low levels of this same variant in the blood. Conclusion: We report a young boy with severe gonadotropin-independent precocious puberty beginning in infancy who developed bilateral diffuse Leydig cell tumors at age 5 years due to a somatic gain-of-function p.Asp578His variant in LHCGR. The gain-of-function nature of the LHCGR variant and the developmental timing of the somatic mutation likely play a role in the risk of tumor formation. Abiraterone (a CYP17A1 inhibitor), in combination with an antiandrogen, aromatase inhibitor, and glucocorticoid, appears to be an effective therapy for severe peripheral precocious puberty in boys. Published by Oxford University Press on behalf of the Endocrine Society 2022.
Context: Autosomal dominant and rarely de novo gain-of-function variants in the LHCGR gene are associated with precocious male puberty, while somatic LHCGR variants have been found in isolated Leydig cell adenomas and Leydig cell hyperplasia. Bilateral diffuse Leydig cell tumor formation in peripheral precocious male puberty has not been reported. Case Description: We present a boy with gonadotropin-independent precocious puberty and rapid virilization beginning in infancy resistant to standard therapy. Treatment with abiraterone in addition to letrozole and bicalutamide proved effective. Bilateral diffuse Leydig cell tumors were identified at age 5 years. Results: Whole-genome sequencing of tumor and blood samples was performed. The patient was confirmed to have bilateral, diffuse Leydig cell tumors harboring the somatic, gain-of-function p.Asp578His variant in the LHCGR gene. Digital droplet polymerase chain reaction of the LHCGR variant performed in tumor and blood samples detected low levels of this same variant in the blood. Conclusion: We report a young boy with severe gonadotropin-independent precocious puberty beginning in infancy who developed bilateral diffuse Leydig cell tumors at age 5 years due to a somatic gain-of-function p.Asp578His variant in LHCGR. The gain-of-function nature of the LHCGR variant and the developmental timing of the somatic mutation likely play a role in the risk of tumor formation. Abiraterone (a CYP17A1 inhibitor), in combination with an antiandrogen, aromatase inhibitor, and glucocorticoid, appears to be an effective therapy for severe peripheral precocious puberty in boys. Published by Oxford University Press on behalf of the Endocrine Society 2022.
Authors: Annemieke M Boot; Serge Lumbroso; Miriam Verhoef-Post; Annette Richter-Unruh; Leendert H J Looijenga; Ada Funaro; Auke Beishuizen; André van Marle; Stenvert L S Drop; Axel P N Themmen Journal: J Clin Endocrinol Metab Date: 2011-04-13 Impact factor: 5.958
Authors: Ellen Werber Leschek; Armando C Flor; Joy C Bryant; Janet V Jones; Kevin M Barnes; Gordon B Cutler Journal: J Pediatr Date: 2017-11 Impact factor: 4.406
Authors: H Kremer; J W Martens; M van Reen; M Verhoef-Post; J M Wit; B J Otten; S L Drop; H A Delemarre-van de Waal; M Pombo-Arias; F De Luca; N Potau; J M Buckler; M Jansen; J S Parks; H A Latif; G W Moll; W Epping; G Saggese; E C Mariman; A P Themmen; H G Brunner Journal: J Clin Endocrinol Metab Date: 1999-03 Impact factor: 5.958
Authors: Edward O Reiter; Nelly Mauras; Ken McCormick; Bindu Kulshreshtha; James Amrhein; Francesco De Luca; Sandra O'Brien; Jon Armstrong; Helena Melezinkova Journal: J Pediatr Endocrinol Metab Date: 2010-10 Impact factor: 1.634
Authors: R V Clark; B D Albertson; A Munabi; F Cassorla; G Aguilera; D W Warren; R J Sherins; D L Loriaux Journal: J Clin Endocrinol Metab Date: 1990-05 Impact factor: 5.958